COMPOSITIONS PHARMACEUTIQUES ET RÉGIMES POSOLOGIQUES DESTINÉS À UNE UTILISATION CLINIQUE D'ANTICORPS ANTI-ANTIGÈNE 2 DE CELLULES DENDRITIQUES DU SANG

Formulations and dosage regimens of anti-Blood Dendritic Cell Antigen 2 (BDCA2) antibodies are provided. These formulations and dosage regimens find use in the treatment of BDCA2-associated disorders such as systematic lupus erythematosus, cutaneous lupus eiythernatosus, and discoid lupus erythemato...

Full description

Saved in:
Bibliographic Details
Main Authors KREBS, Mark, R., H, SULE, Shantanu, MARTIN, David, RABAH, Dania, DAI, David
Format Patent
LanguageFrench
Published 06.03.2019
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

Abstract Formulations and dosage regimens of anti-Blood Dendritic Cell Antigen 2 (BDCA2) antibodies are provided. These formulations and dosage regimens find use in the treatment of BDCA2-associated disorders such as systematic lupus erythematosus, cutaneous lupus eiythernatosus, and discoid lupus erythematosus, and cytokine release syndrome.
AbstractList Formulations and dosage regimens of anti-Blood Dendritic Cell Antigen 2 (BDCA2) antibodies are provided. These formulations and dosage regimens find use in the treatment of BDCA2-associated disorders such as systematic lupus erythematosus, cutaneous lupus eiythernatosus, and discoid lupus erythematosus, and cytokine release syndrome.
Author KREBS, Mark, R., H
MARTIN, David
DAI, David
SULE, Shantanu
RABAH, Dania
Author_xml – fullname: KREBS, Mark, R., H
– fullname: SULE, Shantanu
– fullname: MARTIN, David
– fullname: RABAH, Dania
– fullname: DAI, David
BookMark eNqFjb8OgjAQhxl08N8jmNzmxCJG56atcElpkbYzIaZOBkjwARzlEXyevphF2V3ufsnvu--W0axpG7eI3lTlhdJoUEkNRUbKnFBuDV4s18ANlH5IMQ85UEqo9Fcwrg1KP2jwT7CSQ7gQqMmoASpQjhiwHZEGqSoLDWOKx5H6V-D3QQGUC2HFVydZidNTZkETma6j-a2-924z7VW0PXNDs9h1beX6rr66xj2qnBwOp2NCkn_9B6J7Rp0
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
ExternalDocumentID MA44763A
GroupedDBID EVB
ID FETCH-epo_espacenet_MA44763A3
IEDL.DBID EVB
IngestDate Fri Jul 19 12:48:42 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language French
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_MA44763A3
Notes Application Number: MA20170044763
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20190306&DB=EPODOC&CC=MA&NR=44763A
ParticipantIDs epo_espacenet_MA44763A
PublicationCentury 2000
PublicationDate 20190306
PublicationDateYYYYMMDD 2019-03-06
PublicationDate_xml – month: 03
  year: 2019
  text: 20190306
  day: 06
PublicationDecade 2010
PublicationYear 2019
RelatedCompanies Biogen MA Inc
RelatedCompanies_xml – name: Biogen MA Inc
Score 3.0494232
Snippet Formulations and dosage regimens of anti-Blood Dendritic Cell Antigen 2 (BDCA2) antibodies are provided. These formulations and dosage regimens find use in the...
SourceID epo
SourceType Open Access Repository
SubjectTerms HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Title COMPOSITIONS PHARMACEUTIQUES ET RÉGIMES POSOLOGIQUES DESTINÉS À UNE UTILISATION CLINIQUE D'ANTICORPS ANTI-ANTIGÈNE 2 DE CELLULES DENDRITIQUES DU SANG
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20190306&DB=EPODOC&locale=&CC=MA&NR=44763A
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdR27TsMw0IKCgA0KFa8iD6hMEZSEJB0ilNpua5QXeaBuVVMSiaWt2iBWRvoJfE9-jLMJjwGW6BSfL_JZ53vk7ozQuaqlWt4x28pEU1VF9B9RUvAjlNzITdhzvT2RjqLr6YNEuxveDKtsC1ELI_uEvsjmiCBRE5D3Qp7X858gFpW5lcvL9AlezW57sUVblXcM2g1M4BbtWizwqU9ahFhwdHmhpWkgSPY62gAT2hCpX-yhKypS5r_VSW8XbQZAaVrsobV8UUfb5OvWtTracquf3QBWcrfcR-_EdwM_4rLmFwcDO3RtwpKY3ycswizGYbnqcxdgwJL3G8gByqKYe-UqwuUrTjyGYYbDIxmWwsThnkDD9ML2Yi4iVhEWkCIe_fIN8K-BBCbMcRJHkvNoyKuP0gRHttc_QM0ei8lAgTWOvpk5cu1PVqgNVJvOptkhwpPUEI3dVMPsmNp43BmDGdQ2zez68SrP1Fw_Qo2_aRz_N3CCdsRmyFwt_RTVisVz1gTlXaRnkvMfYNmWyw
link.rule.ids 230,309,783,888,25578,76884
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdR3LToNAcKPVWG9abXxV92DqiWgLUnoghu5uC8rLAqa3piAkXtqmxXj1aD_B7-HHnF3xcdALmbDDbHYns_NgZhahc1mJlayrtaREkWWJ9x-RYvAjpKyTacBztZUIR9FxVTNSbkfXozLbgtfCiD6hL6I5IkhUAvKei_N6_hPEoiK3cnkZP8Gr2U0_1Gmz9I5Bu4EJ3KQ9nfke9UiTEB2OLneoKwoIkrGONsC81niPffbQ4xUp89_qpL-DNn2gNM130Vq2qKEq-bp1rYa2nPJnN4Cl3C330DvxHN8LLFHzi33TGDoGYVFo3UcswCzEw2I1sByAAUvcbyAGKAtCyy1WAS5eceQyDF_YViDCUpjYlsvRML0w3NDiEasAc0jij0HxBvhtIIEJs-3IFuRcOrTKSWmEA8Md7KNGn4XElGCN4-_NHDvG51bIdVSZzqbpAcJJ3OGN3eSO1tWUyaQ7ATOopWlp-_EqS-VMPUT1v2kc_Tdwhqpm6NhjWMjdMdrmjBF5W-oJquSL57QBijyPTwUXPgCcvJm7
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=COMPOSITIONS+PHARMACEUTIQUES+ET+R%C3%89GIMES+POSOLOGIQUES+DESTIN%C3%89S+%C3%80+UNE+UTILISATION+CLINIQUE+D%27ANTICORPS+ANTI-ANTIG%C3%88NE+2+DE+CELLULES+DENDRITIQUES+DU+SANG&rft.inventor=KREBS%2C+Mark%2C+R.%2C+H&rft.inventor=SULE%2C+Shantanu&rft.inventor=MARTIN%2C+David&rft.inventor=RABAH%2C+Dania&rft.inventor=DAI%2C+David&rft.date=2019-03-06&rft.externalDBID=A&rft.externalDocID=MA44763A